Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

iNeo Vac P01

Next Previous
Drug Profile

iNeo Vac P01

Alternative Names: iNeo-Vac-P01; Neoantigen peptides vaccine - Hangzhou Neoantigen Therapeutics

Latest Information Update: 24 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hangzhou Neoantigen Therapeutics
  • Developer Hangzhou Neoantigen Therapeutics; Zhejiang Provincial Peoples Hospitals
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Liver cancer
  • No development reported Oesophageal cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 24 Aug 2025 Phase-I/II clinical trials in Liver cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (SC) (NCT07123545)
  • 28 May 2025 No recent reports of development identified for phase-I development in Oesophageal-cancer in China (Parenteral)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer in China (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top